These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Myeloproliferative syndrome]. Nowotny P; Preussfner S; Konrad H; Engelmann C; Günther I Z Gesamte Inn Med; 1976 Apr; 31(8):250-4. PubMed ID: 986731 [TBL] [Abstract][Full Text] [Related]
6. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders. Pikman Y; Levine RL Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464 [TBL] [Abstract][Full Text] [Related]
7. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation]. Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211 [TBL] [Abstract][Full Text] [Related]
8. Myelofibrosis--what's in a name? Consensus on definition and EUMNET grading. Thiele J; Kvasnicka HM Pathobiology; 2007; 74(2):89-96. PubMed ID: 17587880 [TBL] [Abstract][Full Text] [Related]
9. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era. Zhan H; Spivak JL Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323 [TBL] [Abstract][Full Text] [Related]
10. Classification of Ph-negative chronic myeloproliferative disorders--morphology as the yardstick of classification. Kvasnicka HM; Thiele J Pathobiology; 2007; 74(2):63-71. PubMed ID: 17587877 [TBL] [Abstract][Full Text] [Related]
11. [Diagnostic difficulties in osteomyelosclerosis with myeloid metaplasia in relation to the other components of the myeloproliferative syndrome]. Vilcu A; Hossu T; Popescu ID; Câmpeanu L Med Interna (Bucur); 1973 Mar; 25(3):363-76. PubMed ID: 4527026 [No Abstract] [Full Text] [Related]
13. [Histological diagnosis of Ph-negative myeloproliferative neoplasia. An overview]. Campr V Cesk Patol; 2011 Jul; 47(3):84-93. PubMed ID: 21887923 [TBL] [Abstract][Full Text] [Related]
14. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia). Michiels JJ; Thiele J Int J Hematol; 2002 Aug; 76(2):133-45. PubMed ID: 12215011 [TBL] [Abstract][Full Text] [Related]
15. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy. Tefferi A Am J Hematol; 2008 Jun; 83(6):491-7. PubMed ID: 18429051 [TBL] [Abstract][Full Text] [Related]
16. [Jamshidi biopsy in clinical hematology. Method, indications and results of over 1,000 completed biopsies with special reference to chronic myeloproliferative diseases]. Seewann HL Wien Med Wochenschr Suppl; 1986; 100():1-24. PubMed ID: 3471009 [TBL] [Abstract][Full Text] [Related]
17. [Diagnosis of chronic myeloproliferative diseases based on bone marrow biopsy]. Matolcsy A; Kónya T; Wéber E Orv Hetil; 1992 Jun; 133(26):1617-20, 1625-6. PubMed ID: 1614699 [TBL] [Abstract][Full Text] [Related]
18. [Utility of bone marrow biopsy in the diagnosis of myeloproliferative neoplasm]. Tovar-Bobadilla JL; Ortiz-Hidalgo C Gac Med Mex; 2016; 152(3):407-18. PubMed ID: 27335198 [TBL] [Abstract][Full Text] [Related]
19. Diagnostic criteria of the myeloproliferative disorders (MPD): essential thrombocythaemia, polycythaemia vera and chronic megakaryocytic granulocytic metaplasia. Michiels JJ Neth J Med; 1997 Aug; 51(2):57-64. PubMed ID: 9286142 [TBL] [Abstract][Full Text] [Related]